menu
    • menu
    [{"orgOrder":0,"company":"Theragent","sponsor":"CellVax Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CellVax Selects Theragent as Manufacturing Partner for Phase 2 Clinical Trial for Prostate Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Partnership","leadProduct":"FK-PC101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Theragent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Theragent \/ CellVax Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Theragent \/ CellVax Therapeutics"},{"orgOrder":0,"company":"Theragent","sponsor":"CellVax Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CellVax Submits IND Application for Individualized Cell-based Immunotherapy FK-PC101 with Support of Theragent","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"FK-PC101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Theragent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theragent \/ CellVax Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Theragent \/ CellVax Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Theragent

    Menu

    Theragent

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Theragent

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Theragent

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FK-PC101

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : CellVax Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CellVax Submits IND Application for Individualized Cell-based Immunotherapy FK-PC101 with Support of Theragent

                            Details : FK-PC101 is a novel cancer immunotherapy, it utilizes the patient's own cells to create specific tumor presenting cell. It is being evaluated in phase 2 clinical trials for the treatment of prostate cancer.

                            Brand Name : FK-PC101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            December 20, 2023

                            Lead Product(s) : FK-PC101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : CellVax Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Theragent

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Theragent

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FK-PC101

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : CellVax Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            CellVax Selects Theragent as Manufacturing Partner for Phase 2 Clinical Trial for Prostate Cancer Immunotherap...

                            Details : FK-PC101 is a cell-based autologous cancer vaccine for prostate cancer patients who have a high risk of recurrence after prostatectomy.

                            Brand Name : FK-PC101

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            November 15, 2022

                            Lead Product(s) : FK-PC101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : CellVax Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth